Cargando…
Immunology of COVID‐19 and disease‐modifying therapies: The good, the bad and the unknown
OBJECTIVE: The outbreak of the SARS‐CoV‐2 pandemic, caused by a previously unknown infectious agent, posed unprecedented challenges to healthcare systems and unmasked their vulnerability and limitations worldwide. Patients with long‐term immunomodulatory/suppressive therapies, as well as their physi...
Autores principales: | Zrzavy, Tobias, Wimmer, Isabella, Rommer, Paulus S., Berger, Thomas |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7675490/ https://www.ncbi.nlm.nih.gov/pubmed/33090599 http://dx.doi.org/10.1111/ene.14578 |
Ejemplares similares
-
Longitudinal measurement of cerebrospinal fluid neurofilament light in anti‐N‐methyl‐D‐aspartate receptor encephalitis
por: Macher, Stefan, et al.
Publicado: (2020) -
Circulating T cell subsets are altered in individuals with chronic spinal cord injury
por: Monahan, Rachel, et al.
Publicado: (2015) -
Neurological autoimmune diseases following vaccinations against SARS‐CoV‐2: a case series
por: Kaulen, Leon D., et al.
Publicado: (2021) -
Guilty by association? SARS‐CoV‐2 antibodies and myelin oligodendrocyte glycoprotein antibody‐associated disease
por: Tanasescu, Radu, et al.
Publicado: (2022) -
Is there a correlation between MOG‐associated disorder and SARS‐CoV‐2 infection?
por: Mariotto, Sara, et al.
Publicado: (2022)